Gilead Sciences (GILD) Total Current Liabilities (2009 - 2026)

Gilead Sciences has reported Total Current Liabilities for 18 years, with the latest figure at $9.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 23.23% year-over-year to $9.5 billion; the trailing twelve-month figure through Mar 2026 stood at $9.5 billion (down 23.23% YoY), and the FY2025 full-year result was $11.8 billion, down 1.59% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $9.5 billion, down from $11.8 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $14.0 billion in Q2 2023, with the low at $8.6 billion in Q1 2022.
• Historically, Total Current Liabilities has averaged $11.3 billion across 5 years, with a median of $11.3 billion in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 51.45% — and 2026, when it fell 23.23%.
• Gilead Sciences' Total Current Liabilities stood at $11.2 billion in 2022, then advanced by 0.38% to $11.3 billion in 2023, then advanced by 6.42% to $12.0 billion in 2024, then fell by 1.59% to $11.8 billion in 2025, then decreased by 19.78% to $9.5 billion in 2026.
• The last three Total Current Liabilities figures came in at $9.5 billion (Q1 2026), $11.8 billion (Q4 2025), and $12.3 billion (Q3 2025), per Business Quant data.